the safety and efficacy of fitusiran prophylaxis in patients with hemophilia a and b
Published 2 years ago • 247 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:48
the promise of fitusiran for the treatment of patients with hemophilia a and b
-
3:04
fitusiran significantly reduces bleeding events in patients with hemophilia a or b, with inhibitors
-
3:03
insights into the mechanism of action of fitusiran & the value of this agent in hemophilia treatment
-
3:29
fitusiran prophylaxis shows encouraging results in hemophilia patients
-
7:56
guy young: fitusiran for hemophilia a and b with inhibitors
-
0:59
the safety and efficacy of etavopivat in scd
-
5:06
marstacimab for hemophilia a and b: mechanism of action │pharmacology
-
1:15
the safety and efficacy of peritransplantation ruxolitinib in patients with mf
-
54:50
fitusiran overview with dr. guy young
-
1:34
the future role of ai models in hematology and the need for high-quality data sets
-
1:53
animation heal technology
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:23
association of cxcl13 and t follicular helper cells with hemophilia a inhibitor development
-
0:39
promising therapeutic options emerging in hemophilia
-
7:15
safety and efficacy of valoctocogene roxaparvovec in participants with active fviii inhibitors
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:48:30
safe transfusions: right blood, right patient, right time and place
-
3:23
the importance of proactive hemophilia carrier screening: gender equity in hemophilia care
-
4:06
what are clotting factor replacement therapies and why are they needed?
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
2:07
the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
-
49:15
blood and product safety